Bioaster
6
1
1
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
16.7%
1 terminated/withdrawn out of 6 trials
75.0%
-11.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
REAnimation Low Immune Status Markers
Role: collaborator
Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination
Role: lead
A Single-center, Interventional Diagnostic Study With Minimal Risks and Constraints, Aimed at Longitudinally Evaluating Serum Antibody Levels in Patients With COVID-19 According to the Severity of Their Symptoms.
Role: lead
Human Internal BIOASTER's Samples Collection
Role: lead
BACTERIA ISOLATION FROM STOOLS COLLECTED FROM CENTENARIANS PEOPLE
Role: lead
Characterization of Fecal Microbiota in a Population Aged 50 to 75 Years Targeted by Seasonal Vaccination
Role: lead
All 6 trials loaded